Alzheimer’s disease and its biomarkers in CSF Alzheimer’s disease is a chronic neurodegenerative disorder considered the most common cause of dementia in older people. Although clinical symptoms still form the core of diagnosis, imaging and cerebrospinal fluid biomarkers now play an important role in the diagnostic process. Two important neuropathological features of Alzheimer’s are the … Read more
Amyloid peptides and tau markers in CSF Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), such as β-amyloid 1-42 (Aβ1-42), total tau (tTau) and pTau181, have improved the management of patients with cognitive impairment. Although Aβ1-42 is considered a marker of amyloid pathology, a series of studies have shown that a decrease in CSF Aβ1-42 … Read more
Víctor Montal Blancafort has presented today his Doctoral Thesis entitled “Complex neuroimaging changes in metabolite, cortical structures and regional vulnerabilities in the Alzheimer disease continuum“. The thesis, directed by Dr. Juan Fortea and supervised by Dr. Alberto Lleó, delves into new neuroimaging measures that help establishing the dynamic changes that occur throughout Alzheimer’s disease. Given … Read more
In January 18th 2022, Jordi Pegueroles Monllau presented his doctoral thesis entitled “The role of biomarkers in the current classification systems for Alzheimer’s Disease“. The thesis has been supervised by Dr. Juan Fortea and tutored by Dr. Alberto Lleó. This work has focused on the accuracy of different biomarkers of Alzheimer’s disease and their definition … Read more
GFAP and frontotemporal dementia Frontotemporal dementia is a heterogeneous entity with variable clinical manifestations. As a consequence, it can be confused with psychiatric diseases or other neurodegenerative diseases such as Alzheimer’s disease. Despite the advances in the diagnosis of frontotemporal dementia in the last two decades, we still do not have a precise marker for … Read more
Plasma biomarkers Scientists worldwide are immersed in the race for accurate, non-invasive and accessible biomarkers to detect and diagnose Alzheimer’s Disease. To date, major scientific advances allowed the identification of several biomarkers in cerebrospinal fluid or using positron emission tomography (PET). Yet, these methods are either invasive or expensive and not easily accessible to all … Read more